Liu Shun-qing, Zhu Xiao-jun, Sun Xue-hua, Li Man, Gao Yue-qiu
Department of Hepatology, Shanghai University of Tranditional Chinese Medicine, Shanghai, China.
Zhonghua Gan Zang Bing Za Zhi. 2012 May;20(5):348-52. doi: 10.3760/cma.j.issn.1007-3418.2012.05.009.
To analyse the live pathology characteristics in mild ALT-elevated (1 x ULN less than ALT less than 2 x ULN ) HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) patients, and to explore the influence of the age and HBV DNA level to liver pathology in different HBeAg status patients.
All the patients who met the inclusion criteria form "eleventh five-year plan" National Science and Technology Major Project, the treatment program of integrative traditional and western medicine for CHB were enrolled in this study between October 2009 and March 2011 .B type ultrasound-guided liver biopsy was carried out in all patients and hepatitis B surface antigen (HBsAg) , HBeAg titer as well as HBV DNA level were detected at the same time. Hepatic tissue inflammation and fibrosis degree of patients according to HBeAg-positive and negative, age ( more than or equal to 40 years and less than 40 years), HBV DNA level (more than or equal to 10^5copy/ml and less than l0^5 copy/ml) were compared respectively. Chi-square test was used to compare the constitute percentage between the two samples. Multivariate logistic regression analysis was also performed to evaluate the correlation between different factors.
There were no significant difference in the grade of liver inflammation and the stage of liver fibrosis between 389 HBeAg positive and 126 HBeAg-negative patients (X2=4.326 and X2=3.464, respectively, P values were all more than 0.05). In the group of patients with age less than 40 years, the distribution of different liver inflammation and fibrosis had no significant difference between HBeAg-positive and negative patients (X2=2.543 and X2=5.024, respectively, P values were all more than 0.05). In the group of patient with age more than or equal to 40 years, the percentage of moderate and severe inflammation (G3, G4) HBeAg-positive patients(32.9%) owned is much higher than that of HBeAg-negative patients(16.4%), X2=8.777, P less than 0.05.But the stage of liver fibrosis in HBeAg-positive patients was not significantly different than that of HBeAg-negative ones (X2=0.977, P more than 0.5). In the group of patients with HBV DNA more than or equal to 10^5copy/ml, the percentage of mild inflammation in HBeAg-positive patients (17.5%) was much high than that of HBeAg-negative patients(7.3%), X2=8.851, P less than 0.05. The stage of liver fibrosis between HBeAg-positive and negative patients was no significant difference (X2=8.227, P more than 0.05).In the patients with HBV DNA less than 10^5 copy/ml, The percentage of HBeAg-negative patients(29.6%) with mild inflammation(G1) was much higher than HBeAg-positive patients (6.9%), X2=6.357, P less than 0.05. There was no significant difference in the stage of liver fibrosis between HBeAg-positive and negative patients (X2=4.061, P more than 0.05). The results of multivariate logistic regression analysis showed that age was the independent risk factor for different degree of liver inflammation and fibrosis seriousness.
The status of HBeAg has no association with the grade of liver inflammation and the stage of liver fibrosis in CHB patients with mildly elevated ALT. The percentage of moderate and severe inflammation in the HBeAg-positive patients with age more than or equal to 40 years was significantly elevated. The grade of liver inflammation has significant difference between HBeAg-positive and negative patients with different HBV DNA levels as well.
分析轻度ALT升高(1×ULN<ALT<2×ULN)的HBeAg阳性和HBeAg阴性慢性乙型肝炎(CHB)患者的肝脏病理特征,探讨年龄和HBV DNA水平对不同HBeAg状态患者肝脏病理的影响。
选取符合“十一五”国家科技重大专项CHB中西医结合治疗方案纳入标准的患者,于2009年10月至2011年3月纳入本研究。所有患者均行B型超声引导下肝穿刺活检,同时检测乙型肝炎表面抗原(HBsAg)、HBeAg滴度及HBV DNA水平。根据HBeAg阳性和阴性、年龄(≥40岁和<40岁)、HBV DNA水平(≥10^5拷贝/ml和<10^5拷贝/ml)分别比较患者肝组织炎症和纤维化程度。采用卡方检验比较两组样本的构成比。同时进行多因素logistic回归分析评估不同因素之间的相关性。
389例HBeAg阳性患者与126例HBeAg阴性患者的肝脏炎症分级和纤维化分期差异无统计学意义(X2分别为4.326和3.464,P值均>0.05)。年龄<40岁的患者组中,HBeAg阳性和阴性患者不同肝脏炎症和纤维化分布差异无统计学意义(X2分别为2.543和5.024,P值均>0.05)。年龄≥40岁的患者组中,HBeAg阳性患者中度及重度炎症(G3、G4)的比例(32.9%)明显高于HBeAg阴性患者(16.4%),X2=8.777,P<0.05。但HBeAg阳性患者的肝纤维化分期与HBeAg阴性患者差异无统计学意义(X2=0.977,P>0.5)。HBV DNA≥10^5拷贝/ml的患者组中,HBeAg阳性患者轻度炎症的比例(17.5%)明显高于HBeAg阴性患者(7.3%),X2=8.851,P<0.05。HBeAg阳性和阴性患者的肝纤维化分期差异无统计学意义(X2=8.227,P>0.05)。HBV DNA<10^5拷贝/ml的患者中,HBeAg阴性患者轻度炎症(G1)的比例(29.6%)明显高于HBeAg阳性患者(6.9%),X2=6.357,P<0.05。HBeAg阳性和阴性患者的肝纤维化分期差异无统计学意义(X2=4.061,P>0.05)。多因素logistic回归分析结果显示,年龄是不同程度肝脏炎症和纤维化严重程度的独立危险因素。
ALT轻度升高的CHB患者中,HBeAg状态与肝脏炎症分级和纤维化分期无关。年龄≥40岁的HBeAg阳性患者中度及重度炎症比例明显升高。不同HBV DNA水平的HBeAg阳性和阴性患者肝脏炎症分级也有显著差异。